Home Data Calendar Blog

ANAB

Tables

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31
Common Stock Value		0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.02	0.02	0.02	0.02	0.02	0.02	0.00	NA	NA	NA
Weighted Average Number Of Diluted Shares Outstanding		26.55	26.63	27.95	NA	28.29	28.20	27.71	NA	27.44	27.39	27.36	NA	27.32	27.28	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	20.38	20.27	NA	NA	2.64	3.50	NA
Weighted Average Number Of Shares Outstanding Basic		26.55	26.63	27.95	NA	28.29	28.20	27.71	NA	27.44	27.39	27.36	NA	27.32	27.28	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	20.38	20.27	NA	NA	2.64	2.63	NA
Earnings Per Share Basic		-1.41	-1.50	-1.58	-0.93	-1.18	-1.15	-1.31	-1.19	-0.24	-0.02	-0.66	1.23	-0.87	-0.79	NA	-0.75	-1.15	-0.89	-0.82	-0.64	-0.66	-0.57	-0.63	-0.30	-0.45	-0.13	-0.75	-1.73	-0.42	0.07	-0.34
Earnings Per Share Diluted		-1.41	-1.50	-1.58	-0.93	-1.18	-1.15	-1.31	-1.19	-0.24	-0.02	-0.66	1.23	-0.87	-0.79	NA	-0.75	-1.15	-0.89	-0.82	-0.64	-0.66	-0.57	-0.63	-0.30	-0.45	-0.13	-0.75	-1.73	-0.42	0.05	-0.34

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31
Revenue From Contract With Customer Excluding Assessed Tax		3.32	3.46	1.37	6.81	1.29	1.22	0.97	1.01	20.89	30.03	11.25	60.00	0.00	0.00	15.00	3.00	0.00	5.00	0.00	0.00	5.00	0.00	0.00	3.00	0.00	7.00	0.00	2.75	3.21	5.85	4.87
Revenue From Contract With Customer Including Assessed Tax		3.32	3.46	1.37	6.81	1.29	1.22	0.97	1.01	20.89	30.03	11.25	60.00	0.00	0.00	15.00	3.00	0.00	5.00	0.00	0.00	5.00	0.00	0.00	3.00	0.00	7.00	0.00	2.75	3.21	5.85	4.87
Revenues		3.32	3.46	1.37	6.81	1.29	1.22	0.97	1.01	20.89	30.03	11.25	60.00	0.00	0.00	15.00	3.00	0.00	5.00	0.00	0.00	5.00	0.00	0.00	3.00	0.00	7.00	0.00	2.75	3.21	5.85	4.87
Operating Expenses		41.05	43.60	45.77	32.78	30.93	29.02	32.72	32.17	27.65	30.56	29.61	26.66	24.34	22.64	25.25	25.26	33.74	31.66	24.77	19.66	21.89	14.41	15.76	10.15	9.09	9.55	9.99	5.93	4.29	3.49	6.00
Research And Development Expense		30.88	32.92	34.96	23.37	22.06	20.84	22.52	26.78	22.22	25.31	24.18	21.57	19.54	17.95	20.97	21.43	29.93	27.35	20.63	15.92	17.88	10.58	11.81	7.61	6.70	7.21	7.93	5.02	3.28	2.33	4.79
General And Administrative Expense		10.17	10.68	10.82	9.41	8.86	8.17	10.20	5.39	5.43	5.25	5.42	5.09	4.79	4.69	4.29	3.83	3.81	4.31	4.14	3.74	4.00	3.83	3.95	2.54	2.39	2.35	2.05	0.91	1.01	1.15	1.22
Operating Income Loss		-37.73	-40.14	-44.40	-25.97	-29.63	-27.80	-31.75	-31.16	-6.76	-0.53	-18.36	33.34	-24.34	-22.64	-10.25	-22.26	-33.74	-26.66	-24.77	-19.66	-16.89	-14.41	-15.76	-7.15	-9.09	-2.56	-9.99	-3.17	-1.07	2.36	-1.14
Allocated Share Based Compensation Expense		7.81	8.43	8.86	NA	6.27	6.66	7.74	NA	4.36	3.69	3.31	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Other Comprehensive Income Loss Net Of Tax		1.26	-0.34	1.98	NA	-2.15	-1.43	-2.01	NA	-0.02	-0.07	-0.11	NA	-0.49	-0.39	0.81	NA	-0.09	0.37	0.43	NA	0.14	0.12	-0.38	NA	NA	NA	NA	NA	NA	NA	NA
Net Income Loss		-37.31	-39.84	-44.26	-26.41	-33.50	-32.55	-36.26	-32.54	-6.67	-0.43	-18.16	33.65	-23.77	-21.55	-8.26	-20.26	-31.03	-23.96	-22.08	-16.99	-15.96	-13.62	-15.09	-6.86	-9.09	-2.68	-11.44	-4.58	-1.11	2.32	-0.89
Comprehensive Income Net Of Tax		-36.05	-40.19	-42.28	-25.65	-35.65	-33.98	-38.27	-32.76	-6.69	-0.49	-18.27	33.38	-24.26	-21.94	-7.46	-20.41	-31.13	-23.59	-21.65	-16.68	-15.82	-13.49	-15.89	-7.24	-9.07	-2.73	-11.45	-4.26	-1.11	0.18	-0.89

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31
Assets		487.33	517.10	551.79	610.38	618.50	603.85	625.17	643.07	424.33	426.57	396.42	416.55	384.75	401.75	424.23	435.20	451.50	480.15	494.23	509.00	523.12	306.02	314.84	329.36	121.94	130.41	131.11	62.18	NA	NA	NA
Liabilities And Stockholders Equity		487.33	517.10	551.79	610.38	618.50	603.85	625.17	643.07	424.33	426.57	396.42	416.55	384.75	401.75	424.23	435.20	451.50	480.15	494.23	509.00	523.12	306.02	314.84	329.36	121.94	130.41	131.11	62.18	NA	NA	NA
Stockholders Equity		120.38	148.45	191.09	262.10	277.62	304.31	330.75	356.43	383.61	385.73	381.94	396.73	360.24	381.44	400.56	405.01	420.89	448.42	468.15	486.37	499.68	284.98	294.53	307.58	101.36	109.17	110.11	-38.25	NA	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31
Assets Current		428.00	438.54	437.15	447.20	450.44	452.81	512.41	553.88	386.64	398.06	387.13	396.56	345.81	384.52	371.06	377.73	424.60	430.99	421.94	434.22	503.02	271.82	251.94	252.70	120.33	115.85	110.16	58.21	NA	NA	NA
Cash And Cash Equivalents At Carrying Value		26.30	35.21	94.56	71.31	58.55	71.70	166.41	495.73	336.33	332.25	284.15	250.46	209.15	221.17	165.32	171.02	182.90	146.55	105.85	113.60	293.41	57.06	69.47	81.19	26.67	30.75	96.75	51.23	NA	NA	NA
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents		26.30	35.21	94.56	71.31	58.55	71.70	166.41	495.73	336.39	332.31	284.21	250.52	209.21	221.23	165.38	171.08	182.96	146.61	105.91	113.66	293.47	57.12	69.53	81.25	26.73	30.81	96.81	51.29	47.19	50.65	NA
Receivables Net Current		3.27	3.18	1.52	1.42	1.18	1.03	0.92	0.88	0.76	0.64	1.25	NA	NA	NA	5.00	0.00	NA	5.00	NA	0.00	5.00	NA	NA	0.00	0.00	0.00	0.00	1.23	NA	NA	NA
Prepaid Expense And Other Assets Current		11.68	5.87	4.48	4.54	6.30	9.62	5.87	4.90	11.76	6.51	5.46	2.91	7.47	6.64	3.57	3.51	3.60	3.77	6.10	6.96	4.04	3.76	2.17	2.69	3.12	3.85	1.69	1.63	NA	NA	NA
Available For Sale Securities Debt Securities		426.95	453.52	431.52	512.87	531.93	503.93	430.40	119.47	52.98	64.08	103.27	160.74	165.37	171.03	247.38	257.51	261.52	326.42	386.52	404.31	221.34	246.07	242.57	251.00	90.05	89.52	28.68	NA	NA	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31
Property Plant And Equipment Gross		8.32	7.93	7.72	7.67	7.38	7.31	7.25	7.21	7.18	7.72	6.82	6.73	6.66	6.43	6.41	6.30	6.25	5.91	5.89	5.64	5.44	5.16	4.69	4.64	4.44	4.43	4.41	4.27	NA	NA	NA
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment		6.06	5.91	5.74	5.58	5.41	5.25	5.08	4.92	4.77	5.23	5.07	4.95	5.08	4.94	4.80	4.68	4.56	4.43	4.30	4.20	4.09	4.07	4.03	3.98	3.93	3.89	3.84	3.80	NA	NA	NA
Property Plant And Equipment Net		2.25	2.02	1.98	2.09	1.97	2.06	2.16	2.28	2.41	2.49	1.75	1.78	1.58	1.50	1.61	1.62	1.70	1.48	1.58	1.45	1.34	1.09	0.66	0.67	0.51	0.54	0.57	0.47	NA	NA	NA
Other Assets Noncurrent		0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.26	0.48	0.60	1.11	1.35	1.29	1.48	1.74	1.91	2.09	0.15	0.08	0.32	0.29	0.05	NA	NA	NA	NA	NA	NA	NA
Available For Sale Debt Securities Amortized Cost Basis		429.10	456.92	434.58	517.91	537.73	507.58	432.63	119.68	52.97	64.05	103.17	160.54	164.90	170.07	246.03	256.97	260.80	325.58	386.14	404.48	221.88	246.75	243.37	251.43	90.09	89.58	28.69	NA	NA	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31
Liabilities Current		39.18	41.63	35.80	26.05	21.06	19.87	19.78	16.10	20.89	20.62	14.47	19.82	24.47	20.13	23.25	29.54	29.73	30.62	24.75	21.84	20.87	16.79	14.34	14.09	11.17	10.08	8.13	5.71	NA	NA	NA
Accounts Payable Current		6.52	4.76	3.17	2.78	3.01	1.59	2.48	1.74	5.72	4.10	2.45	4.22	5.48	6.29	8.57	16.24	10.52	10.92	9.07	5.44	6.18	4.43	2.42	2.32	2.56	3.72	2.55	2.28	NA	NA	NA
Other Accrued Liabilities Current		0.69	0.17	0.20	0.30	0.14	0.13	0.13	0.15	0.13	0.49	0.19	0.23	0.22	0.21	0.23	0.27	0.31	0.34	0.46	0.76	0.77	0.31	0.53	0.33	0.17	0.21	0.11	0.08	NA	NA	NA
Accrued Liabilities Current		30.92	35.16	30.96	21.63	16.45	16.71	15.76	12.85	14.07	15.96	11.83	15.26	18.14	12.92	13.78	11.05	15.29	14.10	8.40	8.76	7.14	4.84	4.41	4.88	3.60	3.23	4.33	3.43	NA	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31
Operating Lease Liability Noncurrent		16.49	16.95	17.39	17.81	18.23	18.65	19.06	19.45	19.84	20.22	NA	NA	0.03	0.18	0.42	0.65	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31
Stockholders Equity		120.38	148.45	191.09	262.10	277.62	304.31	330.75	356.43	383.61	385.73	381.94	396.73	360.24	381.44	400.56	405.01	420.89	448.42	468.15	486.37	499.68	284.98	294.53	307.58	101.36	109.17	110.11	-38.25	NA	NA	NA
Common Stock Value		0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.02	0.02	0.02	0.02	0.02	0.02	0.00	NA	NA	NA
Additional Paid In Capital		694.59	686.61	689.07	717.80	707.66	698.70	691.16	678.58	673.00	668.43	664.15	660.66	657.56	654.49	651.68	648.67	644.15	640.55	636.69	633.25	629.89	399.37	395.42	393.02	179.55	178.30	176.51	16.67	NA	NA	NA
Retained Earnings Accumulated Deficit		-571.88	-534.58	-494.73	-450.48	-424.06	-390.56	-358.01	-321.75	-289.21	-282.55	-282.12	-263.96	-297.60	-273.84	-252.29	-244.03	-223.76	-192.73	-168.77	-146.69	-129.70	-113.74	-100.10	-85.00	-78.17	-69.08	-66.40	-54.92	NA	NA	NA
Accumulated Other Comprehensive Income Loss Net Of Tax		-2.35	-3.61	-3.27	-5.25	-6.01	-3.86	-2.43	-0.42	-0.20	-0.18	-0.11	-0.00	0.26	0.75	1.15	0.34	0.48	0.57	0.20	-0.22	-0.54	-0.68	-0.80	-0.43	-0.04	-0.06	-0.01	0.00	NA	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31
Net Cash Provided By Used In Operating Activities		-36.47	-25.41	-24.57	-10.69	-17.75	-24.15	-21.01	-25.30	-7.01	9.59	-23.20	37.58	-17.01	-19.61	-15.11	-15.80	-22.10	-15.52	-16.10	-12.29	-14.86	-8.88	-12.48	-4.81	-3.89	-2.64	-8.10	-5.57	-3.07	1.67	-2.06
Net Cash Provided By Used In Investing Activities		30.64	-20.45	85.40	21.50	-32.43	-71.00	-312.91	-66.69	10.84	37.96	56.73	3.60	4.73	75.39	10.75	4.04	59.86	57.88	9.66	-166.15	24.61	-3.06	2.15	-153.06	-0.49	-62.42	-27.09	-0.00	0.00	-0.01	-0.04
Net Cash Provided By Used In Financing Activities		-3.07	-13.49	-37.57	1.95	37.03	0.43	4.61	251.34	0.24	0.55	0.17	0.13	0.26	0.07	-1.34	-0.11	-1.42	-1.66	-1.30	-1.37	226.60	-0.48	-1.38	212.39	0.30	-0.94	80.70	9.67	-0.38	-0.39	-0.28

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31
Net Cash Provided By Used In Operating Activities		-36.47	-25.41	-24.57	-10.69	-17.75	-24.15	-21.01	-25.30	-7.01	9.59	-23.20	37.58	-17.01	-19.61	-15.11	-15.80	-22.10	-15.52	-16.10	-12.29	-14.86	-8.88	-12.48	-4.81	-3.89	-2.64	-8.10	-5.57	-3.07	1.67	-2.06
Net Income Loss		-37.31	-39.84	-44.26	-26.41	-33.50	-32.55	-36.26	-32.54	-6.67	-0.43	-18.16	33.65	-23.77	-21.55	-8.26	-20.26	-31.03	-23.96	-22.08	-16.99	-15.96	-13.62	-15.09	-6.86	-9.09	-2.68	-11.44	-4.58	-1.11	2.32	-0.89
Depreciation Depletion And Amortization		0.16	0.16	0.17	0.18	0.17	0.16	0.16	0.17	0.17	0.16	0.12	0.14	0.14	0.14	0.14	0.14	0.14	0.12	0.12	0.11	0.09	0.06	0.05	0.05	0.05	0.05	0.04	0.06	0.06	0.06	0.06
Share Based Compensation		7.81	8.43	8.86	NA	6.27	6.66	7.74	NA	4.36	3.69	3.31	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31
Net Cash Provided By Used In Investing Activities		30.64	-20.45	85.40	21.50	-32.43	-71.00	-312.91	-66.69	10.84	37.96	56.73	3.60	4.73	75.39	10.75	4.04	59.86	57.88	9.66	-166.15	24.61	-3.06	2.15	-153.06	-0.49	-62.42	-27.09	-0.00	0.00	-0.01	-0.04
Payments To Acquire Property Plant And Equipment		0.16	0.19	0.17	0.17	0.05	0.08	0.06	0.01	0.17	0.86	0.32	0.31	0.09	0.08	0.09	0.10	0.28	0.24	0.18	0.21	0.32	0.30	0.23	0.12	0.01	0.07	0.09	0.00	0.00	0.01	0.04

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31
Net Cash Provided By Used In Financing Activities		-3.07	-13.49	-37.57	1.95	37.03	0.43	4.61	251.34	0.24	0.55	0.17	0.13	0.26	0.07	-1.34	-0.11	-1.42	-1.66	-1.30	-1.37	226.60	-0.48	-1.38	212.39	0.30	-0.94	80.70	9.67	-0.38	-0.39	-0.28
Payments For Repurchase Of Common Stock		0.00	12.47	37.53	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31
Revenues		3.32	3.46	1.37	6.81	1.29	1.22	0.97	1.01	20.89	30.03	11.25	60.00	0.00	0.00	15.00	3.00	0.00	5.00	0.00	0.00	5.00	0.00	0.00	3.00	0.00	7.00	0.00	2.75	3.21	5.85	4.87
Glaxo Smith Kline		NA	NA	NA	6.80	1.30	1.20	1.00	1.00	20.90	30.00	11.20	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Glaxo Smith Kline, Anaptys Bio Generated Anti L A G3 G S K40974386, Cumulative Milestones Recognized		NA	0.00	8.00	0.00	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Glaxo Smith Kline, Anaptys Bio Generated Anti P D1 J E M P E R L I Dostarlimab, Cumulative Milestones Recognized		NA	NA	93.00	0.00	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Glaxo Smith Kline, Anaptys Bio Generated Anti P D1 Jemperli Dostarlimab, Cumulative Milestones Recognized		0.00	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Glaxo Smith Kline, Anaptys Bio Generated Anti T I M3 G S K4069889 A Cobolimab, Cumulative Milestones Recognized		0.00	0.00	13.00	5.00	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Glaxo Smith Kline, Anaptys Bio Generated Anti T I M3 G S K4069889 A Cobolimab, Phase3 Clinical Trial Initiation First Indication		NA	NA	NA	5.00	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Glaxo Smith Kline, Zejula And Anaptys Bio Generated J E M P E R L I, Royalty Agreement		NA	NA	1.40	1.80	1.30	1.20	1.00	1.00	0.90	0.00	1.20	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Glaxo Smith Kline, Zejula And Anaptys Bio Generated Jemperli, Royalty Agreement		3.30	3.50	NA	NA	1.30	1.20	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Glaxo Smith Kline, Subsequent Event, Anaptys Bio Generated Anti T I M3 G S K4069889 A Cobolimab		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Glaxo Smith Kline, J E M P E R L I Royalty Monetization Agreement		NA	NA	0.60	NA	NA	NA	0.30	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Glaxo Smith Kline, Jemperli Royalty Monetization Agreement		2.50	2.80	NA	NA	0.30	0.60	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Glaxo Smith Kline, Zejula Revenue		NA	0.60	NA	0.90	0.70	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Glaxo Smith Kline, Zejula Royalty Monetization Agreement		0.80	0.70	0.80	NA	NA	NA	0.70	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Revenue From Contract With Customer Excluding Assessed Tax		3.32	3.46	1.37	6.81	1.29	1.22	0.97	1.01	20.89	30.03	11.25	60.00	0.00	0.00	15.00	3.00	0.00	5.00	0.00	0.00	5.00	0.00	0.00	3.00	0.00	7.00	0.00	2.75	3.21	5.85	4.87
Glaxo Smith Kline		NA	NA	NA	6.80	1.30	1.20	1.00	1.00	20.90	30.00	11.20	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Glaxo Smith Kline, Anaptys Bio Generated Anti L A G3 G S K40974386, Cumulative Milestones Recognized		NA	0.00	8.00	0.00	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Glaxo Smith Kline, Anaptys Bio Generated Anti P D1 J E M P E R L I Dostarlimab, Cumulative Milestones Recognized		NA	NA	93.00	0.00	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Glaxo Smith Kline, Anaptys Bio Generated Anti P D1 Jemperli Dostarlimab, Cumulative Milestones Recognized		0.00	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Glaxo Smith Kline, Anaptys Bio Generated Anti T I M3 G S K4069889 A Cobolimab, Cumulative Milestones Recognized		0.00	0.00	13.00	5.00	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Glaxo Smith Kline, Anaptys Bio Generated Anti T I M3 G S K4069889 A Cobolimab, Phase3 Clinical Trial Initiation First Indication		NA	NA	NA	5.00	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Glaxo Smith Kline, Zejula And Anaptys Bio Generated J E M P E R L I, Royalty Agreement		NA	NA	1.40	1.80	1.30	1.20	1.00	1.00	0.90	0.00	1.20	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Glaxo Smith Kline, Zejula And Anaptys Bio Generated Jemperli, Royalty Agreement		3.30	3.50	NA	NA	1.30	1.20	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Glaxo Smith Kline, Subsequent Event, Anaptys Bio Generated Anti T I M3 G S K4069889 A Cobolimab		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Glaxo Smith Kline, J E M P E R L I Royalty Monetization Agreement		NA	NA	0.60	NA	NA	NA	0.30	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Glaxo Smith Kline, Jemperli Royalty Monetization Agreement		2.50	2.80	NA	NA	0.30	0.60	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Glaxo Smith Kline, Zejula Revenue		NA	0.60	NA	0.90	0.70	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Glaxo Smith Kline, Zejula Royalty Monetization Agreement		0.80	0.70	0.80	NA	NA	NA	0.70	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Revenue From Contract With Customer Including Assessed Tax		3.32	3.46	1.37	6.81	1.29	1.22	0.97	1.01	20.89	30.03	11.25	60.00	0.00	0.00	15.00	3.00	0.00	5.00	0.00	0.00	5.00	0.00	0.00	3.00	0.00	7.00	0.00	2.75	3.21	5.85	4.87

Plots across concepts

Line plots across dimensions of each concept